isopropylmethyl ketone oxime O-benzyl ether

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: isopropylmethyl ketone oxime O-benzyl ether
• 英文别名: (E)-3-methylbutan-2-one O-benzyl oxime；(E)-3-methyl-N-phenylmethoxybutan-2-imine
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: BCJKRJRZVQYCGB-ACCUITESSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对甲苯磺酰叠氮 、 isopropylmethyl ketone oxime O-benzyl ether 在 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 silver(I) acetate 、 双三氟甲烷磺酰亚胺银盐 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以68%的产率得到(E)-N-[3-{(benzyloxy)imino}-2-methylbutyl]-4-methylbenzenesulfonamide
  参考文献：
  名称：

  Iridium-Catalyzed Intermolecular Amidation of sp³ C–H Bonds: Late-Stage Functionalization of an Unactivated Methyl Group

  摘要：

  Reported herein is the iridium-catalyzed direct amidation of unactivated sp(3) C-H bonds. With sulfonyl and acyl azides as the amino source, the amidation occurs efficiently under mild conditions over a wide range of unactivated methyl groups with high functional group tolerance. This procedure can be successfully applied for the direct introduction of an amino group into complex compounds and thus can serve as a powerful synthetic tool for late-stage C-H functionalization.

  DOI：

  10.1021/ja501014b
• 作为产物：
  描述：

  3-甲基-2-丁酮 、 苄氧基胺盐酸盐 在 吡啶 作用下， 生成 isopropylmethyl ketone oxime O-benzyl ether
  参考文献：
  名称：

  Iridium-Catalyzed Intermolecular Amidation of sp³ C–H Bonds: Late-Stage Functionalization of an Unactivated Methyl Group

  摘要：

  Reported herein is the iridium-catalyzed direct amidation of unactivated sp(3) C-H bonds. With sulfonyl and acyl azides as the amino source, the amidation occurs efficiently under mild conditions over a wide range of unactivated methyl groups with high functional group tolerance. This procedure can be successfully applied for the direct introduction of an amino group into complex compounds and thus can serve as a powerful synthetic tool for late-stage C-H functionalization.

  DOI：

  10.1021/ja501014b

文献信息

• HIV REPLICATION INHIBITING PYRIMIDINES
  申请人：Janssen Pharmaceutica NV

  公开号：EP3808743A1

  公开（公告）日：2021-04-21

  This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl;n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; substituted Cl-6alkyloxyCl-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6 or a 5-membered heterocycle; X1 is -NR5-, -NH-NH-, -N=N-, -O-, -C(=O)-, C1-4alkanediyl, -CHOH-, -S-, -S(=O)p-, -X2-C1-4alkanediyl- or -C1-4alkanediyl-X2-; R3 is NHR13; NR13R14; -C(=O)-NER13; -C(=O)-NR13R14; -C(=O)-R15; -CH=N-NH-C(=O)-R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; C1-6alkyl substituted with hydroxy and a second substituent; -C(=N-O-R8)-C1-4alkyl; R7; or -X3-R7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl)amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.

  本发明涉及式中的艾滋病毒复制抑制剂 的N-氧化物、药学上可接受的加成盐、季胺及其立体异构体形式，其中含有-a1=a2-a3=a4-和-b1=b2-b3=b4-的环代表苯基、吡啶基、嘧啶基、吡嗪基、哒嗪基；取代的C1-6烷氧基Cl-6烷基羰基；R2 是羟基、卤代、任选取代的 C1-6 烷基、C3-7 环烷基、任选取代的 C2-6 烯基、任选取代的 C2-6 烷炔基、C1-6烷氧基、C1-6烷氧基羰基、羧基、氰基、硝基、氨基、单或双（C1-6烷氧基羰基）、C1-6烷氧基羰基、C1-6烷基羧基、C1-6烷基羰基氨基、单-或二(C1-6烷基)氨基、多卤甲基、多卤甲基氧基、多卤甲基硫代、-S(＝O)pR6、-NH-S(＝O)pR6、-C(＝O)R6、-NHC(＝O)H、-C(＝O)NHNH2、-NHC(＝O)R6、-C(＝NH)R6 或 5 元杂环；X1 是-NR5-、-NH-NH-、-N=N-、-O-、-C(=O)-、C1-4烷二基、-CHOH-、-S-、-S(=O)p-、-X2-C1-4烷二基-或-C1-4烷二基-X2-； R3 是 NHR13；NR13R14；-C(=O)-NER13；-C(=O)-NR13R14；-C(=O)-R15；-CH=N-NH-C(=O)-R16；取代的 C1-6 烷基；任选取代的 C1-6 烷氧基 C1-6 烷基；取代的 C2-6 烯基；取代的 C2-6 烷炔基；被羟基和第二个取代基取代的 C1-6 烷基；-R4为卤代、羟基、C1-6烷基、C3-7环烷基、C1-6烷氧基、氰基、硝基、多卤代C1-6烷基、多卤代C1-6烷氧基、氨基羰基、C1-6烷氧基羰基、C1-6烷基羰基、甲酰基、氨基、单-或二(C1-4烷基)氨基；它们的医药用途、制备工艺和包含它们的药物组合物。
• HIV replication inhibiting pyrimidines
  申请人：Janssen Pharmaceutica NV

  公开号：US10370340B2

  公开（公告）日：2019-08-06

  This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; substituted C1-6alkyloxyC1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocycle; X1 is —NR5—, —NH—NH—, —N═N—, —O—, —C(═O)—, C1-4alkanediyl, —CHOH—, —S—, —S(═O)p—, —X2—C1-4alkanediyl- or —C1-4alkanediyl-X2—; R3 is NHR13; NR13R14; —C(═O)—NHR13; —C(═O)—NR13R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; C1-6alkyl substituted with hydroxy and a second substituent; —C(═N—O—R8)—C1-4alkyl; R7; or —X3—R7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl)amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.

  本发明涉及式中的艾滋病毒复制抑制剂 的N-氧化物、药学上可接受的加成盐、季胺及其立体异构体形式，其中含有-a1=a2-a3=a4-和-b1=b2-b3=b4-的环代表苯基、吡啶基、嘧啶基、吡嗪基、哒嗪基；n 为 0 至 5；m 为 1 至 4；R1 为氢；芳基；甲酰基；C1-6烷基羰基；C1-6烷基；C1-6烷氧基羰基；取代的 C1-6烷基、C1-6烷基羰基、C1-6烷氧基羰基、C1-6烷基羰基氧基、C1-6烷基羧基取代的 C1-6 烷氧基 C1-6 烷基羰基；R2 是羟基、卤代、任选取代的 C1-6 烷基、C3-7 环烷基、任选取代的 C2-6 烯基、任选取代的 C2-6 烷炔基、C1-6 烷氧基、C1-6 烷氧羰基、羧基、氰基、硝基、氨基、单或二(C1-6烷基)氨基、多卤代甲基、多卤代甲基氧基、多卤代甲硫基、-S(═O)pR6、-NH-S(═O)pR6、-C(═O)R6、-NHC(═O)H、-C(═O)NHNH2、-NHC(═O)R6、-C(═NH)R6 或 5 元杂环；X1 是-NR5-、-NH-NH-、-N═N-、-O-、-C(═O)-、C1-4烷二基、-CHOH-、-S-、-S(═O)p-、-X2-C1-4烷二基-或-C1-4烷二基-X2-； R3 是 NHR13； NR13R14；-C(═O)-NHR13；-C(═O)-NR13R14；-C(═O)-R15；-CH═N-NH-C(═O)-R16；取代的 C1-6 烷基；任选取代的 C1-6 烷氧基 C1-6 烷基；取代的 C2-6 烯基；取代的 C2-6 烷炔基；被羟基和第二个取代基取代的 C1-6 烷基；-C(═N-O-R8)-C1-4烷基；R7；或-X3-R7；R4是卤代、羟基、C1-6烷基、C3-7环烷基、C1-6烷氧基、氰基、硝基、多卤代C1-6烷基、多卤代C1-6烷氧基、氨基羰基、C1-6烷氧基羰基、C1-6烷基羰基、甲酰基、氨基、单-或二(C1-4烷基)氨基；它们作为药物的用途、制备工艺和由它们组成的药物组合物。
• Asymmetric reduction of ketoxime derivatives and N-alkylketimines with borane–oxazaborolidine adducts
  作者：Marek P. Krzemiński、Marek Zaidlewicz

  DOI：10.1016/s0957-4166(03)00314-8

  日期：2003.6

  Oxime ethers of acetophenone, isopropyl methyl ketone, and tert-butyl methyl ketone were reduced to the corresponding hydroxylamine ethers of 45-94% ee with borane-oxazaborolidine 1 derived from (-)-norephedrine. A one-pot reduction of acetophenone oxime with 1 to 1-phenylethylhydroxylamine of 87% ee is described. The reduction of 6-methyl-2,3,4,5-tetrahydropyridine and N-methylimines of the above mentioned ketones with borane-B-methyloxazaborolidine adduct 2, derived from (-)-diphenylprolinol, gave the corresponding amines of 40-74% ee. (C) 2003 Elsevier Science Ltd. All rights reserved.
• HIV INHIBITING PYRIMIDINES DERIVATIVES
  申请人：Janssen Pharmaceutica NV

  公开号：EP2298761B1

  公开（公告）日：2020-03-25
• Pyrimidine derivatives for the prevention of hiv infection
  申请人：Heeres Jan

  公开号：US20070021449A1

  公开（公告）日：2007-01-25

  This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein the ring containing -a 1 =a 2 -a 3 =a 4 - and -b 1 =b 2 -b 3 =b 4 - represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; and pharmaceutical compositions comprising them.